See more : Thunder Bridge Capital Partners IV Inc. (THCPW) Income Statement Analysis – Financial Results
Complete financial analysis of G&E Herbal Biotechnology Co., Ltd. (4911.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of G&E Herbal Biotechnology Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Magnite, Inc. (MGNI) Income Statement Analysis – Financial Results
- Nemetschek SE (NEM.DE) Income Statement Analysis – Financial Results
- PT Provident Agro Tbk (PALM.JK) Income Statement Analysis – Financial Results
- Three F Co.,Ltd. (7544.T) Income Statement Analysis – Financial Results
- EKO International Corp. (EKNL) Income Statement Analysis – Financial Results
G&E Herbal Biotechnology Co., Ltd. (4911.TWO)
About G&E Herbal Biotechnology Co., Ltd.
G&E Herbal Biotechnology Co., Ltd., a biopharmaceutical company, focuses on the development and commercialization of novel botanical extraction technology and products. It offers botanical anti-aging cosmetic products, such as facial foam cleanser and cleansing essence, botanical extract toner, lightening lotion, essential oil, and moisturizing serum and cream; SR-100 botanical essence and bromelain illuminating cleansing mousse; and hepato protective agent capsules. The company also provides botanical healthcare products comprising ArthrEnergy, Jujubes Polysaccharide, Diabecut, HepatoClean, Astragali Radix, Goji, Prosta, and SR-100 capsules; and adult products. In addition, it is developing Solarise injection for the treatment of gynecologic, head, and neck cancer; Apocin capsule to treat non-small cell lung cancer; and SR-T100 Gel for the treatment of common and genital warts. Further, the company manufactures technology development for various dietary supplements, as well as provides technical advisory services to other biotechnology organizations. G&E Herbal Biotechnology Co., Ltd. was founded in 2002 and is based in Tainan City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 181.44M | 64.61M | 24.57M | 28.23M | 17.55M |
| Cost of Revenue | 36.86M | 25.25M | 14.95M | 16.22M | 23.33M |
| Gross Profit | 144.59M | 39.35M | 9.63M | 12.01M | -5.78M |
| Gross Profit Ratio | 79.69% | 60.91% | 39.17% | 42.56% | -32.92% |
| Research & Development | 24.60M | 14.39M | 12.54M | 12.72M | 10.11M |
| General & Administrative | 15.63M | 10.06M | 9.18M | 10.45M | 0.00 |
| Selling & Marketing | 23.67M | 9.43M | 7.47M | 4.32M | 0.00 |
| SG&A | 39.30M | 19.48M | 16.65M | 14.77M | 11.91M |
| Other Expenses | 0.00 | 1.14M | 821.00K | 1.80M | -882.00K |
| Operating Expenses | 63.90M | 33.87M | 29.19M | 27.49M | 22.90M |
| Cost & Expenses | 100.76M | 59.12M | 44.13M | 43.70M | 46.23M |
| Interest Income | 4.40M | 604.00K | 517.00K | 613.00K | 894.00K |
| Interest Expense | 4.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 9.33M | 9.40M | 9.34M | 9.22M | 9.22M |
| EBITDA | 99.84M | 16.63M | -10.23M | -6.26M | -19.45M |
| EBITDA Ratio | 55.02% | 25.73% | -41.61% | -22.17% | -104.21% |
| Operating Income | 80.68M | 7.23M | -19.56M | -15.47M | -28.68M |
| Operating Income Ratio | 44.47% | 11.19% | -79.61% | -54.81% | -163.36% |
| Total Other Income/Expenses | 9.82M | 1.74M | 1.34M | 2.42M | 1.16M |
| Income Before Tax | 90.50M | 7.23M | -18.22M | -13.06M | -27.52M |
| Income Before Tax Ratio | 49.88% | 11.19% | -74.16% | -46.26% | -156.75% |
| Income Tax Expense | 18.10M | -154.00K | 1.66M | 1.24M | -4.15M |
| Net Income | 72.40M | 7.38M | -19.88M | -14.30M | -23.37M |
| Net Income Ratio | 39.90% | 11.42% | -80.92% | -50.66% | -133.10% |
| EPS | 1.30 | 0.13 | -0.36 | -0.26 | -0.40 |
| EPS Diluted | 1.23 | 0.13 | -0.36 | -0.26 | -0.40 |
| Weighted Avg Shares Out | 55.66M | 55.66M | 55.66M | 55.66M | 59.00M |
| Weighted Avg Shares Out (Dil) | 59.05M | 55.66M | 55.66M | 55.66M | 59.00M |
Source: https://incomestatements.info
Category: Stock Reports